PIRAMAL PATENTS A PHARMA FORMULA
Article Abstract:
Mr Ajay Piramal, chairman of the Rs543-crore Nicholas Piramal, has built his business entirely through takeovers and alliances. Nicholas Piramal owns various over-the- counter (OTC) brands, has numerous marketing alliances with global drug companies and joint ventures with some of them. Ajay Piramal follows a different principal in his pharma business in that he focuses on brands, marketing and distribution and gives little importance to research and exports. Nicholas Piramal has a field force of 1,600 for sales of Rs400 crore as against Glaxo's force of 1,300 for domestic sales of Rs900 crore. However it is his huge sales force which has enabled it to clinch various deals. Nicholas Piramal has a marketing tie up with Reckitt & Colman (R&C) of the UK for products like Dettol and Disprin. It also has a tie up with Boots Plc also of the UK for Strepsils, Icy and Sweetex. Nicholas Piramal's other partners include US ophthalmic products company Allergan, immunology products company Cytran, surgical and hospital products firm Stryker Corp and footcare products from Scholl. The Sarabhai Group has a 50:50 joint venture with Piramal to market its pain killers, arthritis and cancer drugs. The pharma group's turnover, including Nicholas Piramal and the R&C joint venture may cross Rs1,000 crore. Nicholas Piramal has bought the Hoechst research centre for Rs20 crore and is planning to do contract research for multinational companies at this centre. It is also expanding the family-run charitable Gopikrishna Piramal Hospital to facilitate the clinical and bio- equivalence studies required for drug research. (tsm)
Comment:
Owns various over-the-counter brands, & has numerous marketing alliances w/ global drug companies, company profile
Publication Name: BusinessWorld
Subject: Business, international
ISSN:
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
IN HOT PURSUIT OF THE POTENCY PILL
Article Abstract:
Indian pharma companies like Cipla, Orchid Chemicals & Pharmaceuticals, Kopran and Dr Reddy's Laboratories are busy preparing the Indian version of Pfizer's potency pill, Viagra, to tap the huge potential existing in the market. In anticipation, the scrips of these companies have risen sharply on the bourses. Orchid's scrip on the Bombay Stock Exchange gained 36 percent to reach Rs123 from Rs30 on May 18, 1998, Cipla's share price rose from Rs779 to Rs846 and the scrips of Kopran and Dr Reddy's also increased, but not to the same extent. (gsh)
Comment:
India: Indian pharma cos are busy preparing Indian version of Pfizer's potency pill Viagra to tap huge potential existing in mkt
Publication Name: BusinessWorld
Subject: Business, international
ISSN:
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
NICHOLAS IN INDUSTRIAL LIAISON WITH MIT
Article Abstract:
Nicholas Piramal India Ltd (NPIL) plans to join the industrial liaison programme (ILP) of the Massachusetts Institute of Technology (MIT). NPIL will be the first Indian pharma company to join such a programme. The ILP involves 200 companies including eight international pharma companies. ILP will serve as a forum for the continuing education of NPIL's scientists and also help them become aware of the latest advances in science and technology. (um)(vr)
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: KERALA SOAPS LOOKS TO AFRICA FOR TURNAROUND. HLL LOWERS PRICES OF DETERGENTS. SOAPY GAUNTLET
- Abstracts: 4 STATE SUGAR UNITS TO START OPERATIONS DHAMPUR SUGAR PUTS 3 UNITS ON THE BLOCK
- Abstracts: HOTEL LEELAVENTURE LIMITED ITDC PLANS THREE-STAR HOTEL IN JOINT VENTURE WITH TTDC
- Abstracts: AV BIRLA GROUP MAY UNIFY CEMENT BRANDS, SALES FORCE CEMENT GLUT SHOWS THE DOOR TO 14 PROJECTS
- Abstracts: THE HIGH COST OF WRONG REFORM PLAYING POWER FOOTSIE, THE PRIVATE SECTOR WAY